The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer

YILDIZ R., Benekli M., Buyukberber S., Kaya A. O., Ozturk B., Yaman E., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.136, no.10, pp.1471-1476, 2010 (SCI-Expanded) identifier identifier identifier


Bevacizumab-based chemotherapy has become the standard of care in metastatic colorectal cancer (MCRC). We aimed to measure the levels of serum soluble FAS, FASL, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its death receptors DR4 and DR5 in MCRC patients and to define prognostic significance of these parameters in response to bevacizumab in these patients.